Cassava Sciences (SAVA) said it will change its name to Filana Therapeutics, reflecting its focus on developing drugs that target the filamin A protein to treat central nervous system disorders.
The company is working on therapies for conditions such as tuberous sclerosis complex-related epilepsy and other diseases linked to abnormal filamin A activity.
The company’s shares will begin trading under the new ticker FLNA on the Nasdaq Capital Market starting March 11, 2026.
“The launch of Filana Therapeutics represents a new beginning for our Company. Growing evidence suggests that filamin A is an important regulator of neuronal development and that modulating filamin A may provide a new approach to treating CNS disorders such as TSC-related epilepsy. Centering our identity on filamin A reflects our dedication to rigorous scientific discovery and to bringing new treatment options to patients and their families,” said Rick Barry, president and chief executive officer of Filana Therapeutics.
SAVA shares rose +2.4% premarket at $2.17.